tinzaparin sodium: clinical use

Prescribing considerations

• Confirm the indication is covered by this adult treatment product.
• Assess bleeding risk, renal function, previous heparin exposure and planned invasive or neuraxial procedures.
• Low-molecular-weight heparins are not interchangeable; switching requires product-specific instructions.
• The selected syringe contains sodium metabisulfite, which may rarely cause severe hypersensitivity or bronchospasm; use caution in asthma.
• Use in children is not established sufficiently for a licensed dosing recommendation.

Contraindications and cautions

• Hypersensitivity to tinzaparin or an excipient.
• Current or previous immune-mediated heparin-induced thrombocytopenia.
• Active major bleeding or a condition strongly predisposing to major bleeding.
• Septic endocarditis.
• Use for treatment in a patient receiving neuraxial anaesthesia.

Monitoring

• Check platelet count before treatment and periodically thereafter; remain vigilant for heparin-induced thrombocytopenia.
• Assess renal function, especially in older adults or suspected impairment.
• Measure potassium before and during treatment in patients at risk of hyperkalaemia.
• Anti-Xa monitoring is not routine but may be considered in selected patients with severe renal impairment when treatment is judged necessary.
• Monitor for bleeding, anaemia, thrombosis and injection-site reactions.

Clinical pharmacology

A porcine-derived low-molecular-weight heparin that potentiates antithrombin-mediated inhibition of activated coagulation factors, predominantly factor Xa, with additional anti-IIa activity. After subcutaneous injection, bioavailability based on anti-Xa activity is high; elimination involves reticuloendothelial and renal pathways.

Formulation and product differences

• The selected product is a graduated, variable-volume pre-filled syringe intended for single use.
• It contains sodium metabisulfite but not the benzyl alcohol used in some multidose vial formulations.
• The solution may become yellow during storage but should not be used if cloudy or containing sediment.
• The pre-filled syringe has a needle safety device; unused contents must be discarded.

Injection

Route: Parenteral

Strengths: 10000 units/mL, 20000 units/mL